Τίτλος:
Ciprofloxacin in critically ill children
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Data regarding the use of fluoroquinolones in critically ill children are scarce. We present our experience regarding the use of ciprofloxacin in this specific patient population. We prospectively identified all paediatric patients who received ciprofloxacin treatment in the intensive care unit of the tertiary care P. & A. Kyriakou Children's Hospital during a three year period (2005 to 2008). Eighteen paediatric patients (mean age 23 months, 12 females) who received intravenous ciprofloxacin were identified. Various underlying diseases, including malignancy and immunodeficiency, were observed. None of the evaluated patients had cystic fibrosis. Fourteen patients had bacteraemia (mainly caused from Gram-negative pathogens), one had Stenotrophomonas maltophilia pneumonia, while no pathogen was identified in three patients. The latter patients received ciprofloxacin due to the severity of their clinical manifestations. All patients with microbiologically documented infections recovered. Three deaths attributed to the underlying diseases were noted. Within a 10-day follow-up, two cases of diarrhoea, one case of vomiting and one case of reversible supraventricular tachycardia were noted. No case of QT prolongation was noted. The short-term follow-up hampered any assessment of joint and cartilage toxicity, potentially associated with ciprofloxacin treatment. Our study suggests that ciprofloxacin may be a useful option for critically ill children without cystic fibrosis. Even though firm conclusions regarding the safety profile of ciprofloxacin in critically ill children could not be drawn, our study provides useful information regarding short-term adverse events associated with ciprofloxacin.
Συγγραφείς:
Sideri, G.
Kafetzis, D.A.
Vouloumanou, E.K.
Papadatos, J.H.
Papadimitriou, M.
Falagas, M.E.
Περιοδικό:
Romanian Journal of Anaesthesia and Intensive Care
Εκδότης:
Australian Society of Anaesthetists
Λέξεις-κλειδιά:
amikacin; cefotaxime; ceftazidime; ceftriaxone; ciprofloxacin; clindamycin; cotrimoxazole; gentamicin; meropenem; metronidazole; netilmicin; pentamidine; piperacillin plus tazobactam; teicoplanin; tigecycline; timentin; vancomycin, abdominal pain; Acinetobacter baumannii; Acinetobacter infection; acute granulocytic leukemia; antibiotic therapy; arthropathy; article; bacterial pneumonia; cardiomyopathy; cause of death; central nervous system infection; child; child death; childhood cancer; chondropathy; clinical article; comorbidity; controlled study; craniencephalic injury; critically ill patient; diarrhea; disease association; disease severity; Down syndrome; drug induced headache; drug safety; drug treatment failure; Enterobacter aerogenes; ependymoma; female; follow up; Gram negative bacterium; Gram negative sepsis; human; immune deficiency; intensive care unit; intracranial hypertension; kidney dysfunction; Klebsiella pneumoniae; Klebsiella pneumoniae infection; lung dysplasia; male; multiple organ failure; myelitis; pancreas pseudocyst; pancreatitis; pneumocystosis; preschool child; prospective study; Pseudomonas aeruginosa; Pseudomonas infection; QT prolongation; rheumatic fever; Serratia infection; Serratia marcescens; Staphylococcus aureus; Staphylococcus infection; Stenotrophomonas maltophilia; supraventricular tachycardia; tendon disease; tertiary health care; traumatic brain injury; vomiting; Wiskott Aldrich syndrome
DOI:
10.1177/0310057x1103900416
